Inclusion criteria: <br>1.Patients must have histologically confirmed soft tissue sarcoma (STS)<br>Note: Evidence of disease progression at study entry is required.<br>2.Treated in any order (neoadjuvant, adjuvant or for metastatic disease) with an anthracycline containing chemotherapy <br>(The participant may have had any number of prior systemic cytotoxic therapies for advanced/metastatic disease. All previous anticancer treatments must be completed = 3 weeks (21 days) prior to first dose of study drug.)<br>3.No progression on prior therapy with anthracyclines or within three months after stopping this therapy<br>4.Signed written informed consent<br>5.Men and women aged = 18 years<br>6.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.<br>7.Locally advanced (unresectable) or metastatic disease<br>8.Presence of measurable or non-measurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Eisenhauer et al., 2009)<br>9.Adequate haematologic, organ, and coagulation within 2 weeks (14 days) prior to enrollment:<br>•Absolute neutrophil count (ANC) = 1,500/mm3; G-CSF is not permitted within 2 weeks (14 days) prior to enrollment<br>•Platelet count = 100,000/mm3<br>•Creatinine clearance = 45 mL/min (calculated by using the Cockcroft-Gault formula (refer to study protocol Appendix 4)<br>•Total bilirubin = upper limit of normal (ULN). In patients with Gilbert’s Syndrome, total bilirubin should be < 3 mg/dL<br>•AST/ALT = 3.0 x upper limit of normal (ULN); in case of liver involvement, AST/ALT = 5.0 x are acceptable<br>•Haemoglobin = 9 g/dl. If haemoglobin <9 g/dl, blood transfusion is permitted. If haemoglobin cannot be enhanced to = 9 g/dl, patient cannot be included into the study<br>•International Normalized Ration (INR) = 1.5 or prothrombin time (PT) = 1.5 x ULN<br>•Partial thromboplastin time (PTT or aPTT) = 1.5 x ULN if not on anticoagulant therapy. For patients receiving anticoagulants, coagulation parameters within the intended or expected range for their therapeutic use are allowed. <br>•If routine urinalysis =2+ proteinuria, patient must have =1000 mg protein on a 24-hour urine, or urine protein/creatinine ratio =1 on spot urine<br>10.Left ventricular ejection fraction (LVEF) =50% assessed within 28 days prior to enrollment<br>11.Females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrollment (refer to study protocol Appendix 3)<br>12.Females of child-bearing potential and males and must agree to use highly effective contraceptive precautions during the trial and up to 6 months following the last dose of study drug (refer to study protocol Appendix 3)<br>13.The participant has, in the opinion of the investigator, a life expectancy of at least 3 months<br><br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) no<br>F.1.2.1 Number of subjects for this age range 44<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 16<br>